Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants.

Epilepsy therapy is largely symptomatic and no effective therapy is available to prevent epileptogenesis. We therefore analysed the potential of stem cell-derived brain implants and of paracrine adenosine release to suppress the progressive development of seizures in the rat kindling-model. Embryonic stem (ES) cells, engineered to release the inhibitory neuromodulator adenosine by biallelic genetic disruption of the adenosine kinase gene (Adk-/-), and respective wild-type (wt) cells, were differentiated into neural precursor cells (NPs) and injected into the hippocampus of rats prior to kindling. Therapeutic effects of NP-derived brain implants were compared with those of wt baby hamster kidney cells (BHK) and adenosine releasing BHK cell implants (BHK-AK2), which were previously shown to suppress seizures by paracrine adenosine release. Wild-type NP-graft recipients were characterized by an initial delay of seizure development, while recipients of adenosine releasing NPs displayed sustained protection from developing generalized seizures. In contrast, recipients of wt BHK cells failed to display any effects on kindling development, while recipients of BHK-AK2 cells were only moderately protected from seizure development. The therapeutic effect of Adk(-/-)-NPs was due to graft-mediated adenosine release, since seizures could transiently be provoked after blocking adenosine A1 receptors. Histological analysis of NP-implants at day 26 revealed cell clusters within the infrahippocampal cleft as well as intrahippocampal location of graft-derived cells expressing mature neuronal markers. In contrast, BHK and BHK-AK2 cell implants only formed cell clusters within the infrahippocampal cleft. We conclude that ES cell-derived adenosine releasing brain implants are superior to paracrine adenosine release from BHK-AK2 cell implants in suppressing seizure progression in the rat kindling-model. These findings may indicate a potential antiepileptogenic function of stem cell-mediated adenosine delivery.

[1]  R. Simon,et al.  Neuroprotection in Ischemic Mouse Brain Induced by Stem Cell-Derived Brain Implants , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  B. Fredholm,et al.  Adenosine A1 receptors are crucial in keeping an epileptic focus localized , 2006, Experimental Neurology.

[3]  K. Houkin,et al.  I.v. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat , 2005, Neuroscience.

[4]  S. Masino,et al.  Adenosine and ATP Link PCO2 to Cortical Excitability via pH , 2005, Neuron.

[5]  Thomas Rülicke,et al.  Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. , 2005, Brain : a journal of neurology.

[6]  O. Brüstle,et al.  Suppression of Kindled Seizures by Paracrine Adenosine Release from Stem Cell–Derived Brain Implants , 2005, Epilepsia.

[7]  H. Beck,et al.  Functional Properties of ES Cell–Derived Neurons Engrafted into the Hippocampus of Adult Normal and Chronically Epileptic Rats , 2005, Epilepsia.

[8]  U. Dirnagl,et al.  Neuroprotective role of astrocytes in cerebral ischemia: Focus on ischemic preconditioning , 2005, Glia.

[9]  W. Pralong,et al.  Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts , 2005, Experimental Neurology.

[10]  D. Boison.  Adenosine and Epilepsy: From Therapeutic Rationale to New Therapeutic Strategies , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  T. Tcheng,et al.  Preemptive Low‐frequency Stimulation Decreases the Incidence of Amygdala‐kindled Seizures , 2005, Epilepsia.

[12]  E. Simpson,et al.  Engineering embryonic stem cell derived glia for adenosine delivery , 2004, Neuroscience Letters.

[13]  Christian E Elger,et al.  Chronic epilepsy and cognition , 2004, The Lancet Neurology.

[14]  O. Lindvall,et al.  Stem cell therapy for human neurodegenerative disorders–how to make it work , 2004, Nature Medicine.

[15]  Marius Wernig,et al.  Functional Integration of Embryonic Stem Cell-Derived Neurons In Vivo , 2004, The Journal of Neuroscience.

[16]  Hannah R Cock,et al.  Focal treatment for refractory epilepsy: hope for the future? , 2004, Brain Research Reviews.

[17]  C. Svendsen,et al.  Stem cells as a potential treatment of neurological disorders. , 2004, Current opinion in pharmacology.

[18]  K. Houkin,et al.  BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  J. Fritschy,et al.  Overexpression of Adenosine Kinase in Epileptic Hippocampus Contributes to Epileptogenesis , 2004, The Journal of Neuroscience.

[20]  Marius Wernig,et al.  Functional Integration of Embryonic Stem Cell-Derived Neurons in Hippocampal Slice Cultures , 2003, The Journal of Neuroscience.

[21]  R. Cunha,et al.  Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats , 2003, The European journal of neuroscience.

[22]  J. Fritschy,et al.  Seizure Suppression by Adenosine A1 Receptor Activation in a Mouse Model of Pharmacoresistant Epilepsy , 2003, Epilepsia.

[23]  N. Déglon,et al.  Seizure Suppression by Adenosine‐releasing Cells Is Independent of Seizure Frequency , 2002, Epilepsia.

[24]  Wolfgang Löscher,et al.  Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy , 2002, Epilepsy Research.

[25]  O. Wiestler,et al.  Ammon's Horn Sclerosis: A Maldevelopmental Disorder Associated with Temporal Lobe Epilepsy , 2002, Brain pathology.

[26]  N. Déglon,et al.  Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E A Kowaluk,et al.  Therapeutic potential of adenosine kinase inhibitors , 2000, Expert opinion on investigational drugs.

[28]  C E Elger,et al.  Cellular pathology of hilar neurons in Ammon's horn sclerosis , 1999, The Journal of comparative neurology.

[29]  Ingmar Blümcke,et al.  Molecular neuropathology of human mesial temporal lobe epilepsy , 1999, Epilepsy Research.

[30]  R. McKay,et al.  In vitro-generated neural precursors participate in mammalian brain development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Muriel T. Davisson,et al.  Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice , 1997, Nature Genetics.

[32]  T. Stone,et al.  Alkylxanthine adenosine antagonists and epileptiform activity in rat hippocampal slices in vitro , 1997, Experimental Brain Research.

[33]  A. Nath,et al.  Characterization of Inhibitor‐Sensitive and ‐Resistant Adenosine Transporters in Cultured Human Fetal Astrocytes , 1996, Journal of neurochemistry.

[34]  M. Segal,et al.  Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro , 1996, Mechanisms of Development.

[35]  J. Geiger,et al.  Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation , 1996, Journal of Neuroscience Methods.

[36]  E. Lothman,et al.  Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling , 1994, Brain Research.

[37]  M. Dragunow,et al.  Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms , 1994, Neuroscience.

[38]  H. Benveniste,et al.  Determination of Brain Interstitial Concentrations by Microdialysis , 1989, Journal of neurochemistry.

[39]  G. Buzsáki,et al.  Suppression and induction of epileptic activity by neuronal grafts. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Faull,et al.  Neuroprotective effects of adenosine. , 1988, Trends in pharmacological sciences.

[41]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[42]  G. V. Goddard,et al.  Is Adenosine an Endogenous Anticonvulsant? , 1985, Epilepsia.

[43]  Peter Schubert,et al.  The anticonvulsive action of adenosine: a postsynaptic, dendritic action by a possible endogenous anticonvulsant , 1984, Brain Research.

[44]  R. Racine.  Kindling: the first decade. , 1978, Neurosurgery.

[45]  B. Fredholm,et al.  Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. , 2005, Annual review of pharmacology and toxicology.

[46]  K. Houkin,et al.  Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  P. Svenningsson,et al.  Adenosine and brain function. , 2005, International review of neurobiology.

[48]  J. Engel.  So what can we conclude--do seizures damage the brain? , 2002, Progress in brain research.

[49]  U Klingmüller,et al.  Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors , 2002, Gene Therapy.

[50]  B. Fredholm.  Adenosine and neuroprotection. , 1997, International review of neurobiology.

[51]  B. Fredholm.  Chapter 11 Adenosine and Neuroprotection , 1996 .

[52]  J. McNamara,et al.  The kindling model of epilepsy: a critical review. , 1985, CRC critical reviews in clinical neurobiology.

[53]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .